Skip to main content
. 2023 Oct 18;12:RP88865. doi: 10.7554/eLife.88865

Table 1. Patient characteristics (n = 16).

Clinical characteristics ARVC GE patients (n = 8) ARVC PKP2 patients (n = 8) p value
Male 2 {25} 2 {25} -
Age at CMR, years 31.0 [22-45] 35.3 [18-55] 0.55
Age at first clinical VT, years 34.0 [22-45] 31.0 [17-55] 0.94
ICD implantation 7 {88} 7 {88} -
Beta blocker 8 {100} 5 {63} 0.056
Sodium channel blocker 2 {25} 3 {38} 0.59
Syncope 2 {25} 2 {25} -
Cardiac function
RV hypokinesis 4 {50} 6 {75} 0.15
RVEF (%) 37.6±5.5 36.1±9.7 0.76
RVCO (L/min) 4.7±1.2 4.9±0.9 0.72
RVEDVI (ml/m2) 131.8±31.2 144.5±63.3 0.66
LVEF (%) 57.2±6.5 55.7±10.0 0.74
LVEDVI (ml/m2) 89.3±9.2 89.7±23.0 0.97
LVCO (L/min) 5.1±0.8 5.0±0.9 0.86

Values are given as n {%}, mean [range], or mean ± standard deviation. p Values were calculated using Student’s t-test and z-test with p ≤ 0.05 as statistically significant. CMR = cardiac magnetic resonance; VT = ventricular tachycardia; ICD = implantable cardiac defibrillator; RV = right ventricle; LV = left ventricle; RVEF = right ventricular ejection fraction; RVCO = right ventricular cardiac output; RVEDVI = right ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVCO = left ventricular cardiac output; LVEDVI = left ventricular end-diastolic volume index. The cardiac function parameters were obtained from CMR reports.